Biofidelity Awarded £500K Innovate UK Grant to Develop Noninvasive MDx Tools

Jul

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Menu

Biofidelity Awarded £500K Innovate UK Grant to Develop Noninvasive MDx Tools

To read the full story....

Breaking News

ReviveMed, Bristol Myers Squibb to Study Metabolomics for Cancer Immunotherapy

Jiangsu Hengrui's Pyrotinib Demonstrates Anti-Tumor Activity in HER2-Positive Lung Cancer

Syapse Partners With Ajou University Hospital to Expand Real-World Data Network in Asia

Canadian Consortium Launches C$2.6M Liquid Biopsy Initiative to Improve Targeted Cancer Treatment

Genetic Alterations in Cyclin-Dependent Kinases Highlight Potential Cancer Treatment Approach

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

Featured White Papers

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

What's Popular?

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

MD Anderson, Sanofi Announce Five-Year Precision Oncology Partnership

Case Study Supports Potential First-Line Use of Vitrakvi in NTRK Fusion-Positive Glioblastoma

Notable's Drug Sensitivity Assay IDs Rx for Blood Cancer Patients When NGS Can't, Small Study Shows

Genetic Alterations in Cyclin-Dependent Kinases Highlight Potential Cancer Treatment Approach

Sponsorships